Patent ID: 8999638
Filing Date: 2015-04-07
Classification: A61K,A61P,C12Q

Abstract:
1. A method of administering iloperidone or a metabolite thereof to a human individual, the method comprising: determining or having determined the individual's KCNQ1 genotype at position 79764 of SEQ. ID. 1; and in the case that the individual's KCNQ1 genotype at position 79764 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, administering to the individual a first quantity of iloperidone or a metabolite thereof, and in the case that the individual's KCNQ1 genotype at position 79764 of SEQ. ID. 1 is not associated with an increased risk of QT prolongation, administering to the individual a second quantity of iloperidone or a metabolite thereof, wherein the first quantity is less than the second quantity, wherein the KCNQ1 genotype associated with an increased risk of QT prolongation is GG at position 79764 of SEQ. ID. 1, and the KCNQ1 genotype not associated with an increased risk of QT prolongation is non-GG at position 79764 of SEQ. ID. 1.